PL2812337T3 - Pochodne furo[3,2-b]pirydynowe jako inhibitory tbk1 oraz ikk - Google Patents
Pochodne furo[3,2-b]pirydynowe jako inhibitory tbk1 oraz ikkInfo
- Publication number
- PL2812337T3 PL2812337T3 PL13700192T PL13700192T PL2812337T3 PL 2812337 T3 PL2812337 T3 PL 2812337T3 PL 13700192 T PL13700192 T PL 13700192T PL 13700192 T PL13700192 T PL 13700192T PL 2812337 T3 PL2812337 T3 PL 2812337T3
- Authority
- PL
- Poland
- Prior art keywords
- tbk1
- furo
- pyridine derivatives
- ikk inhibitors
- ikk
- Prior art date
Links
- 239000003458 I kappa b kinase inhibitor Substances 0.000 title 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical class C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12000842 | 2012-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2812337T3 true PL2812337T3 (pl) | 2017-01-31 |
Family
ID=47557136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13700192T PL2812337T3 (pl) | 2012-02-09 | 2013-01-03 | Pochodne furo[3,2-b]pirydynowe jako inhibitory tbk1 oraz ikk |
Country Status (25)
Country | Link |
---|---|
US (1) | US9045493B2 (pl) |
EP (1) | EP2812337B1 (pl) |
JP (1) | JP6138831B2 (pl) |
KR (1) | KR20140120371A (pl) |
CN (1) | CN104093722B (pl) |
AR (1) | AR089945A1 (pl) |
AU (1) | AU2013218354B2 (pl) |
BR (1) | BR112014017762A8 (pl) |
CA (1) | CA2863985C (pl) |
DK (1) | DK2812337T3 (pl) |
ES (1) | ES2606637T3 (pl) |
HK (1) | HK1202550A1 (pl) |
HR (1) | HRP20161578T1 (pl) |
HU (1) | HUE032203T2 (pl) |
IL (1) | IL233981A (pl) |
LT (1) | LT2812337T (pl) |
MX (1) | MX350112B (pl) |
PL (1) | PL2812337T3 (pl) |
PT (1) | PT2812337T (pl) |
RS (1) | RS55388B1 (pl) |
RU (1) | RU2622034C2 (pl) |
SG (1) | SG11201404630UA (pl) |
SI (1) | SI2812337T1 (pl) |
WO (1) | WO2013117285A1 (pl) |
ZA (1) | ZA201406581B (pl) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201303109D0 (en) | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
TW201613916A (en) * | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
KR101949624B1 (ko) | 2014-09-26 | 2019-02-18 | 길리애드 사이언시즈, 인코포레이티드 | Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체 |
CA2985859A1 (en) * | 2015-06-29 | 2017-01-05 | Merck Patent Gmbh | Tbk/ikk.epsilon. inhibitor compounds and uses thereof |
CA3006772A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
US10894784B2 (en) | 2015-12-18 | 2021-01-19 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
DE102016113714A1 (de) | 2016-07-26 | 2018-02-01 | Rosa Karl | Transfektionsverfahren mit nicht-viralen Genliefersystemen |
GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
TWI802605B (zh) | 2017-10-17 | 2023-05-21 | 德商默克專利有限公司 | 嘧啶TBK/IKKε抑制劑化合物及其用途 |
US10722514B2 (en) * | 2017-11-13 | 2020-07-28 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof |
US11084829B2 (en) | 2018-09-24 | 2021-08-10 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof |
TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
DK3873903T3 (da) | 2018-10-31 | 2024-04-02 | Gilead Sciences Inc | Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2024033281A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | Furo pyrimidine derivates |
WO2024033280A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CN1125817C (zh) | 1996-02-13 | 2003-10-29 | 曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
TWI319387B (en) * | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
CN100386329C (zh) * | 2002-06-06 | 2008-05-07 | 贝林格尔.英格海姆药物公司 | 取代的3-氨基-噻吩并[2,3-b]吡啶-2-羧酸酰胺化合物及其制备方法和用途 |
US7276519B2 (en) * | 2002-11-25 | 2007-10-02 | Wyeth | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
CA2591211A1 (en) * | 2004-12-17 | 2006-06-22 | Parichehr Malherbe | Thieno-pyridine derivatives as gaba-b allosteric enhancers |
US20090076009A1 (en) | 2006-05-03 | 2009-03-19 | Arnould Jean-Claude Retired | Thiazole derivatives and their use as anti-tumour agents |
WO2009030890A1 (en) | 2007-09-03 | 2009-03-12 | University Court Of The University Of Dundee | Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma |
WO2009053737A2 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
GB0903759D0 (en) | 2009-03-04 | 2009-04-15 | Medical Res Council | Compound |
CA2772625A1 (en) * | 2009-09-03 | 2011-03-10 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
EP2488503A1 (en) | 2009-10-12 | 2012-08-22 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon |
GB201012105D0 (en) * | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
AU2011295441B2 (en) * | 2010-08-27 | 2015-04-09 | Merck Patent Gmbh | Furopyridine derivatives |
-
2013
- 2013-01-03 AU AU2013218354A patent/AU2013218354B2/en not_active Ceased
- 2013-01-03 BR BR112014017762A patent/BR112014017762A8/pt not_active IP Right Cessation
- 2013-01-03 SI SI201330419A patent/SI2812337T1/sl unknown
- 2013-01-03 US US14/377,528 patent/US9045493B2/en not_active Expired - Fee Related
- 2013-01-03 PL PL13700192T patent/PL2812337T3/pl unknown
- 2013-01-03 WO PCT/EP2013/000006 patent/WO2013117285A1/en active Application Filing
- 2013-01-03 PT PT137001921T patent/PT2812337T/pt unknown
- 2013-01-03 JP JP2014555961A patent/JP6138831B2/ja not_active Expired - Fee Related
- 2013-01-03 ES ES13700192.1T patent/ES2606637T3/es active Active
- 2013-01-03 EP EP13700192.1A patent/EP2812337B1/en active Active
- 2013-01-03 RU RU2014136366A patent/RU2622034C2/ru not_active IP Right Cessation
- 2013-01-03 MX MX2014009173A patent/MX350112B/es active IP Right Grant
- 2013-01-03 CN CN201380008648.7A patent/CN104093722B/zh not_active Expired - Fee Related
- 2013-01-03 SG SG11201404630UA patent/SG11201404630UA/en unknown
- 2013-01-03 KR KR1020147024966A patent/KR20140120371A/ko not_active Application Discontinuation
- 2013-01-03 LT LTEP13700192.1T patent/LT2812337T/lt unknown
- 2013-01-03 CA CA2863985A patent/CA2863985C/en not_active Expired - Fee Related
- 2013-01-03 RS RS20161082A patent/RS55388B1/sr unknown
- 2013-01-03 HU HUE13700192A patent/HUE032203T2/en unknown
- 2013-01-03 DK DK13700192.1T patent/DK2812337T3/en active
- 2013-02-08 AR ARP130100402A patent/AR089945A1/es unknown
-
2014
- 2014-08-06 IL IL233981A patent/IL233981A/en active IP Right Grant
- 2014-09-08 ZA ZA2014/06581A patent/ZA201406581B/en unknown
-
2015
- 2015-04-01 HK HK15103290.4A patent/HK1202550A1/zh not_active IP Right Cessation
-
2016
- 2016-11-28 HR HRP20161578TT patent/HRP20161578T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
JP6138831B2 (ja) | 2017-05-31 |
EP2812337A1 (en) | 2014-12-17 |
PT2812337T (pt) | 2016-12-14 |
JP2015510511A (ja) | 2015-04-09 |
CA2863985C (en) | 2020-08-11 |
AU2013218354B2 (en) | 2017-01-19 |
SI2812337T1 (sl) | 2017-01-31 |
US20150005284A1 (en) | 2015-01-01 |
RU2014136366A (ru) | 2016-03-27 |
HK1202550A1 (zh) | 2015-10-02 |
AR089945A1 (es) | 2014-10-01 |
CN104093722B (zh) | 2016-07-27 |
WO2013117285A1 (en) | 2013-08-15 |
SG11201404630UA (en) | 2014-09-26 |
CN104093722A (zh) | 2014-10-08 |
HRP20161578T1 (hr) | 2016-12-30 |
DK2812337T3 (en) | 2016-11-07 |
RU2622034C2 (ru) | 2017-06-09 |
BR112014017762A2 (pl) | 2017-06-20 |
KR20140120371A (ko) | 2014-10-13 |
IL233981A (en) | 2016-09-29 |
HUE032203T2 (en) | 2017-08-28 |
BR112014017762A8 (pt) | 2017-07-11 |
AU2013218354A1 (en) | 2014-09-25 |
ES2606637T3 (es) | 2017-03-24 |
EP2812337B1 (en) | 2016-09-07 |
RS55388B1 (sr) | 2017-03-31 |
US9045493B2 (en) | 2015-06-02 |
CA2863985A1 (en) | 2013-08-15 |
LT2812337T (lt) | 2016-11-25 |
MX2014009173A (es) | 2014-08-27 |
MX350112B (es) | 2017-08-28 |
ZA201406581B (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS55388B1 (sr) | Furo[3, 2 - b]piridin derivati kao tbk1 i ikk inhibitori | |
HRP20171724T1 (hr) | Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze | |
IL257312A (en) | H1-pyrazolo[b-4,3]pyridine compounds and their therapeutic use | |
IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
IL235819A0 (en) | Preparation of pyrrolo[b–3,2]pyridines | |
ZA201405070B (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors | |
IL232717B (en) | 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives | |
SG11201408816QA (en) | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | |
IL228555A0 (en) | The history of thiani[3,2–d]pyrimidines and their use to treat cardiac arrhythmias | |
EP2835372A4 (en) | THIOPHENE [2, 3-D] PYRIMIDINE DERIVATIVE AND METHOD OF PREPARATION AND USE | |
SG11201500883YA (en) | 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | |
EP2912169A4 (en) | ARTEMISININE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIMALARIAMIDAL | |
UA80820U (en) | 2-AMINO-4-METHYL-9-(3,4-METHYLENEDIOXYPHENYL)-7-OXO-3-CYANO-6,7,8,9-TETRAHYDROPYRIDO[2',3':4,5]THIENO[3,2-b]PYRIDINE | |
GB201211756D0 (en) | Novel isothiazolo [4,3-b]pyridines | |
GB201221462D0 (en) | Novel isothiazolo[5,4-b]pyridines | |
GB201213663D0 (en) | Novel isothiazolo[5,4-b]pyridines | |
UA80818U (en) | 2-AMINO-4-METHYL-9- (3,4,5-TRIMETHOXYPHENYL)-7-OXO-3-CYANO-6,7,8,9-TETRAHYDROPYRIDO[2',3':4,5]THIENO[3,2-b]PYRIDINE | |
GB201300892D0 (en) | Novel isothiazolo[4,3-b]pyridines | |
UA79045U (en) | 2-amino-4,7-dimethyl-8-phenylcarbamoyl-9-(2-chlorophenyl)-3-cyanopyrido[2',3' : 4,5]thieno[2,3-b]pyridine |